Merck & Co. Inc.
📊 Market Data
📈 Income Statement (SEC Verified)
| Metric | 2024-06 | 2024-09 | 2024-12 | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | $4.48B | $4.04B | $16.98B | $3.66B | $3.32B | $3.86B | $14.36B | $3.72B |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.01 |
💹 Profitability & Margins
🏦 Balance Sheet
💸 Cash Flow Statement
🎯 Analyst Ratings & Price Targets
Consensus Recommendation
BuyBased on 27 analyst opinions
| Target High | $150.00 |
| Target Mean | $129.74 |
| Target Low | $100.00 |
| Current Price | $112.56 |
| Upside Potential | +15.3% |
🏢 Company Information
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Fl...
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Employees | 73,000 |
| Headquarters | Rahway, NJ, United States |
| Website | https://www.merck.com |
| Exchange | NYQ |
| Currency | USD |
| Shares Outstanding | 2.47B |
| Insider Ownership | 0.1% |
| Institutional Ownership | 82.0% |
| EPS (TTM) | 3.55 |
| EPS (Forward) | 9.57 |
| PEG Ratio | 5.23 |
| Next Earnings Date | 2026-08-04 |